Pharmaceutical stalwart Novo Nordisk (NVO) can’t seem to get anything good going these days. As TipRanks’ Vince Condarcuri ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Novo Nordisk also boasted a 55.6% share of the GLP-1 drug space, compared to 54.4% as of August 2023. The company's most famous brands, Wegovy and Ozempic, are both GLP-1s.

Finally, Novo Nordisk's recent issue is less damaging to its prospects than AstraZeneca's. For all those reasons, the former looks like a far better buy than the latter right now. The Motley Fool ...

The Bill and Melinda Gates Foundation is a charitable organization that has spent tens of billions of dollars fighting global ...

With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...

As weight-loss drugs have exploded in popularity this past year, part of the craze has been members of the public wondering which celebrities are on Ozempic.

Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk NVO revealed 8 unusual trades. Delving into the details, we found 50% of ...

Danish pharma company Novo Nordisk, makers of weight-loss drugs Ozempic and Wegovy, plans to expand production based on a takeover of US health products manufacturer Catalent, in a deal worth ...

Globally, Novo Nordisk holds 65% of the market for GLP-1 medicines by volume, which is a big part of the reason that it was able to generate trailing-12-month operating income of $17.2 billion.